SUBSCRIBE
SUBSCRIBE

MedX announces issuance of shares in connection with Advertising Services Agreement

June 2, 2020 | 
2 min read

MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that pursuant to the agreement for an online marketing and awareness program through AGORACOM, that was announced in the Press Release dated June 1, 2020, it has settled the first payment to AGORACOM, in the amount of 12,000 plus HST, or $13,560, by issuance on June 1, 2020, of 90,400 shares at an issue price of $0.15 per share.

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that pursuant to the agreement for an online marketing and awareness program through AGORACOM, that was announced in the Press Release dated June 1, 2020, it has settled the first payment to AGORACOM, in the amount of 12,000 plus HST, or $13,560, by issuance on June 1, 2020, of 90,400 shares at an issue price of $0.15 per share. The issue price of the shares was determined by using the closing price of the Shares of the Company on the TSX Venture Exchange on May 29, 2020, being the last trading day before the date of issuance. The shares were issued pursuant to the prospectus exemption contained in section 2.24 of National Instrument 45-106 Prospectus Exemptions, and are not subject to trading restrictions pursuant to the provisions of National Instrument 45-102, Resale of Securities since the criteria contained in NI 45-102 2.6(3) are met.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

Contacts

Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229

Source: MedX Health Corp.